
    
      Participants depending on their groups will receive either two doses of Menactra vaccine
      concomitantly with the routinely recommended vaccines or one dose of MenC vaccine
      concomitantly with the routinely recommended vaccines and will be monitored for safety and
      immunogenicity. The duration of each subject's participation in the trial will be
      approximately 7 months.
    
  